Pharmacogenetic studies of change in cortisol on ecstasy (MDMA) consumption

Journal of Psychopharmacology

Volumn 26, Issue 3, 2012, Pages 419-428

  Wolff, Kim ^a   Tsapakis, Evangelia M ^a   Pariante, Carmine M ^a   Kerwin, Robert W ^a   Forsling, Mary L ^b   Aitchison, Katherine J ^a,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

4 methylenedioxyamphetamine (MDMA); Catechol O methyltransferase (COMT); cortisol; CYP2D6; ecstasy; genetic; glucocorticoid; N methyl 3; polymorphism; recreational drugs; serotonin transporter

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; HYDROCORTISONE; SEROTONIN TRANSPORTER;

5HTTLPR GENE; ADULT; ARTICLE; BLOOD SAMPLING; COMT GENE; CONTROLLED STUDY; CYP2D6 GENE; DRUG SCREENING; DRUG USE; ENZYME ACTIVITY; FEMALE; GENE ACTIVITY; GENE PRODUCT; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; URINALYSIS;

ADULT; AMINO ACID SUBSTITUTION; BIOLOGICAL MARKERS; BIOTRANSFORMATION; CATECHOL O-METHYLTRANSFERASE; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROTOXICITY SYNDROMES; PITUITARY-ADRENAL SYSTEM; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STREET DRUGS; YOUNG ADULT;

EID: 84857890764     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111415737     Document Type: Article

References (61)

1. Aardal E, Holm AC. Cortisol in saliva-reference ranges and relation to cortisol in serum. Eur J Clin Chem Clin Biochem. 1995 ; 33: 927-932 (Pubitemid 26012948)
2. Caufriez A, Moreno-Reyes R, Leproult R, Vertongen F, Van Cauter E, Copinschi G. Immediate effects of an 8-h advance shift of the rest-activity cycle on 24-h profiles of cortisol. Am J Physiol Endocrinol Metab. 2002 ; 282: E1147 - E1153
3. Cole JC, Sumnall HR, Smith GW, Rostami-Hodjegan A. Preliminary evidence of the cardiovascular effects of polysubstance misuse in nightclubs. J Psychopharmacol. 2005 ; 19: 67-70
4. Collier DA, Stober G, Li T, Heils A, Catalano M, Di Bella D, et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry. 1996 ; 1: 453-460 (Pubitemid 126439785)
5. Dafters RI. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav. 1995 ; 58: 877-882
6. de la Torre R, Farre M, Mathuna BO, Roset PN, Pizarro N, Segura M, et al. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur J Clin Pharmacol. 2005 ; 61: 551-554 (Pubitemid 41218828)
7. de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, et al. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit. 2004 ; 26: 137-144 (Pubitemid 38501207)
8. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001 ; 98: 6917-6922 (Pubitemid 32538317)
9. Farré M, de la Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M, et al. Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl). 2004 ; 173: 364-375 (Pubitemid 38703810)
10. Forsling M, Fallon JK, Kicman T, Hutt AJ, Cowan DA, Henry JA. Arginine vasopressin release in response to the administration of 3,4- methylenedioxymethamphetamine ("ecstasy"): Is metabolism a contributory factor?. J Pharm Pharmacol. 2001 ; 53: 1357-1363 (Pubitemid 32982252)
11. Forsling ML, Williams A, Wheeler M. The effect of melatonin administration on pituitary hormone secretion in man. Clin Endocrin. 1999 ; 51: 637-642
12. Galfi M, Radacs M, Juhasz A, Laszlo F, Molnar A, Laszlo FA. Serotonin-induced enhancement of vasopressin and oxytocin secretion in rat neurohypophyseal tissue culture. Regul Pept. 2005 ; 127: 225-231 (Pubitemid 40179260)
13. Gerra G, Bassignana S, Zaimovic A, Moi G, Bussandri M, Caccavari R, et al. Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('ecstasy') use history: correlation with dopamine receptor sensitivity. Psychiatry Res. 2003 ; 120: 115-124 (Pubitemid 37180002)
14. Gilhooly TC, Daly AK. CYP2D6 deficiency, a factor in ecstasy related deaths?. Br J Clin Pharmacol. 2002 ; 54: 69-70 (Pubitemid 36124757)
15. Glatz K, Mossner R, Heils A, Lesch KP. Glucocorticoid-regulated human serotonin transporter (5-HTT) expression is modulated by the 5-HTT gene-promotor-linked polymorphic region. J Neurochem. 2003 ; 86: 1072-1078 (Pubitemid 37022183)
16. Gouzoulis E, Borchardt D, Hermle L. A case of toxic psychosis induced by 'eve' (3,4-methylene-dioxyethylam-phetamine). Arch Gen Psychiatry. 1993 ; 50: 75 (Pubitemid 23026995)
17. Harris DS, Baggott M, Mendelson JH, Mendelson JE, Jones RT. Subjective and hormonal effects of 3,4 methylene dioxymethamphetamine (MDMA) in humans. Psychopharmacol (Berl). 2002 ; 162: 396-405 (Pubitemid 35001902)
18. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996 ; 66: 2621-2624 (Pubitemid 26159101)
19. Heller T, Kirchheiner J, Armstrong VW, Luthe H, Tzvetkov M, Brockmoller J, et al. AmpliChip CYP450 GeneChip: a new gene chip that allows rapid and accurate CYP2D6 genotyping. Ther Drug Monit. 2006 ; 28: 673-677 (Pubitemid 44564068)
20. Henry JA. Metabolic consequences of drug misuse. Br J Anaesth. 2000 ; 85: 136-142 (Pubitemid 30417229)
21. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA ("Ecstasy") induces vasopressin secretion. Lancet. 1998 ; 351: 1784 (Pubitemid 28269192)
22. Heydari A, Yeo KR, Lennard MS, Ellis SW, Tucker GT, Rostami-Hodjegan A. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab Dispos. 2004 ; 32: 1213-1217 (Pubitemid 39410904)
23. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006 ; 78: 815-826
24. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry. 2009 ; 195: 30-38
25. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry. 1991 ; 30: 1139-1166
26. Kripke DF, Youngstedt SD, Elliott JA, Tuunainen A, Rex KM, Hauger RL. Circadian phase in adults of contrasting ages. Chronobiol Int. 2005 ; 22: 695-709 (Pubitemid 41361732)
27. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996 ; 6: 243-250 (Pubitemid 26226317)
28. Leproult R, Copinschi G, Buxton O, Van Cauter E. Sleep loss results in an elevation of cortisol levels the next evening. Sleep. 1997 ; 20: 865-870 (Pubitemid 27524715)
29. Libiseller K, Pavlic M, Grubwieser P, Rabl W. Ecstasy-deadly risk even outside rave parties. Forensic Sci Int. 2005 ; 153: 227-230 (Pubitemid 41219679)
30. Lora-Tamayo C, Tena T, Rodriguez A. Amphetamine derivative related deaths. Forensic Sci Int. 1997 ; 85: 149-157 (Pubitemid 27089452)
31. Martin TL. Three cases of fatal paramethoxyamphetamine overdose. J Anal Toxicol. 2001 ; 25: 649-651 (Pubitemid 32939076)
32. Mas M, Farré M, de la Torre R, Roset PN, Ortuno J, Segura J, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther. 1999 ; 290: 136-145 (Pubitemid 29302313)
33. McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, et al. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology. 2005 ; 30: 1741-1750 (Pubitemid 43086031)
34. Meikle A, Tasende C, Garofalo EG, Forsberg M. Priming effect of exogenous oestradiol on luteinizing hormone secretion in prepubertal lambs. Animal Reprod Sci. 1998 ; 54: 75-85 (Pubitemid 29000563)
35. Mintel Market Research (2004) Retrieved from http://www.mintel.com/ nightclubs-uk-december2004.html (accessed 11 August 2008).
36. Moss HB, Vanyukov M, Yao JK, Kirillova GP. Salivary cortisol responses in prepubertal boys: the effects of parental substance abuse and association with drug use behavior during adolescence. Biol Psychiatry. 1999 ; 45: 1293-1299 (Pubitemid 29292505)
37. Mougin F, Bourdin H, Simon-Rigaud ML, Nguyen NU, Kantelip JP, Davenne D. Hormonal responses to exercise after partial sleep deprivation and after a hypnotic drug-induced sleep. J Sports Sci. 2001 ; 19: 89-97 (Pubitemid 32170873)
38. Nash JF. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci. 1990 ; 47: 2401-2408
39. Ott J Analysis of Human Genetic Linkage. Baltimore, MD: John Hopkins University Press ; 1991 :
40. Parrott AC. Chronic tolerance to recreational MDMA (3,4- methylenedioxymethamphetamine) or Ecstasy. J Psychopharmacol. 2005 ; 19: 71-83
41. Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang YY, et al. Effect of a triallelic functional polymorphism of the serotonin-transporter- linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry. 2006 ; 163: 48-51 (Pubitemid 43050102)
42. Poland RE. Diminished corticotropin and enhanced prolactin responses to 8-hydroxy-2(di-n-propylamino)tetralin in methylenedioxymethamphetamine pretreated rats. Neuropharmacology. 1990 ; 29: 1099-1101 (Pubitemid 20372958)
43. Ricaurte GA, DeLanney LE, Wiener SG, Irwin I, Langston JW. 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates. Brain Res. 1988 ; 474: 359-363
44. RoeS. (2005) Drug Misuse Declared: Findings from the 2004/05 British Crime Survey: England and Wales. Home Office Statistical Bulletin, http://www.homeoffice.gov.uk/rds/pdfs05/hosb1605.pdf (accessed 11 August 2008).
45. Schwab M, Seyringer E, Brauer RB, Hellinger A, Griese EU. Fatal MDMA intoxication. Lancet. 1999 ; 353: 593-594
46. Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. Lancet. 1999 ; 354: 1435-1439 (Pubitemid 29494756)
47. Spiegel K, Tasali E, Penev P, Van Cauter E. Sleep curtailment in healthy young men is associated with decreased leptin levels: elevated ghrelin levels and increased hunger and appetite. Ann Intern Med. 2004 ; 141: 846-850 (Pubitemid 39601178)
48. Spielman RS, Weinshilboum RM. Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet. 1981 ; 10: 279-290 (Pubitemid 12249733)
49. Spina E, Martines C, Caputi AP, Cobaleda J, Piñas B, Carrillo JA, et al. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol. 1991 ; 41: 467-470
50. Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998 ; 3: 508-511 (Pubitemid 28515526)
51. Tancer ME, Johanson CE. The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend. 2003 ; 65: 97-101 (Pubitemid 33063665)
52. Tandon K, Huezo-Diaz P, Kinirons M, Gustafsson L, Gill M, McGuffin P, et al Oral presentation at the Fourth Annual Pharmacogenetics in Psychiatry Meeting. New York: ; 2005 :
53. Tsapakis EM, Wolff K, Huezo-Diaz P, Winstock A, Kerwin R, Forsling M, et al. Positive association of CYP2D6 and COMT variants with ecstasy-induced changes in water homeostatic measures. Am J Med Genet B. 2006 ; 141B: 789
54. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol. 1994 ; 47: 1151-1156
55. Van Cauter E. Diurnal and ultradian rhythms in human endocrine function: a minireview. Horm Res. 1990 ; 34: 45-53
56. Vgontzas AN, Zoumakis E, Bixler EO, Lin HM, Follett H, Kales A, et al. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab. 2004 ; 89: 2119-2126 (Pubitemid 38619840)
57. Weaver IC, Diorio J, Seckl JR, Szyf M, Meaney MJ. Early environmental regulation of hippocampal glucocorticoid receptor gene expression: characterization of intracellular mediators and potential genomic target sites. Ann N Y Acad Sci. 2004 ; 1024: 182-212 (Pubitemid 38879602)
58. Weinshilboum RM, Raymond FA. Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet. 1977 ; 29: 125-135 (Pubitemid 8070429)
59. Wolff K, Hay AWM, Sherlock K, Conner M. Contents of ecstasy. Lancet. 1995 ; 346: 1100-1101
60. Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, et al. Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol. 2006 ; 20: 400-410
61. Young EA, Abelson J, Lightman SL. Cortisol pulsatility and its role in stress regulation and health. Front Neuroendocrinol. 2004 ; 25: 69-76 (Pubitemid 39572200)